Login to Your Account

Diversity must be more than a buzz word in clinical trials

By Mari Serebrov
Washington Editor

Tuesday, April 1, 2014

If the FDA approved drugs and devices based on the populations adequately tested in clinical trials, most medical products would be indicated only for white men younger than 65.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription